Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study

Inflammatory Bowel Diseases

Volumn 18, Issue 6, 2012, Pages 1006-1010

  Meucci, Gianmichele ^f   Fasoli, Renato ^a   Saibeni, Simone ^b   Valpiani, Daniela ^c   Gullotta, Renzo ^d   Colombo, Enrico ^e   D'Incà, Renata ^f   Terpin, Maddalena ^g   Lombardi, Giovanni ^h  

^a Unità Complessa di Medicina   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

^d Clinica San Carlo   (Italy)

^e RHO HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g Ospedale Civile di Legnano   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

endoscopic remission; mesalazine; mucosal healing; ulcerative colitis

Indexed keywords

MESALAZINE;

ADULT; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; EROSION; FECES; FEMALE; HUMAN; INTESTINE MOTILITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLONOSCOPY; ENDOSCOPY; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; YOUNG ADULT;

EID: 84861338466     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21838     Document Type: Article

References (32)

1. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 338-346.
2. Kornbluth A, Sachar DB,. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol. 2010; 105: 501-523
3. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422.
4. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011; 9: 483-489.
5. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132: 763-186.
6. Daperno M, Sostegni R, Pera A, et al. The role of endoscopic assessment in ulcerative colitis in the era of infliximab. Dig Liver Dis. 2008; 40 (suppl 2): S220-224.
7. Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 796-800.
8. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 1867-1871.
9. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005; 54: 960-965.
10. Vecchi M, Meucci G, Gionchetti P, et al. Comparison of oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized, multicenter italian study. Aliment Pharm Ther. 2001; 15: 251-256.
11. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629.
12. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 1660-1666.
13. Kornbluth A, Kamm MA, Lichtenstein GR, et al. Symptomatic resolution is an inadequate predictor of complete colonic. Mucosal healing in mild-to-moderate ulcerative colitis. Gastroenterology. 2007; 132: A506 [abstract].
14. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 95-102.
15. Hanauer SB,. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998; 4: 79-83.
16. Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000; 14: 1191-1198.
17. Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005; 100: 355-361.
18. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954; 2: 375-378.
19. Beattie RM, Nicholls SW, Domizio P, et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1996; 22: 373-379.
20. Oshitani N, Matsumoto T, Jinno Y, et al. Prediction of short-term outcome for patients with active ulcerative colitis. Dig Dis Sci. 2000; 45: 982-986.
21. Yamamoto T, Umegae S, Matsumoto K,. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010; 16: 1905-1911.
22. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120: 13-20.
23. Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut. 1990; 31: 179-183.
24. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991; 32: 174-178.
25. Leo S, Leandro G, Di Matteo G, et al. Ulcerative colitis in remission: it is possible to predict the risk of relapse? Digestion. 1989; 44: 217-221.
26. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulceratve colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol. 1997; 32: 1005-1012.
27. Sewitch MJ, Abrahamowicz M,. Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 1535-1544.
28. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006; 51: 2165-2169.
29. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 39-43.
30. Shale MJ,., Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191-198.
31. Kane SV, Cohen RD,., Aikens JE, et al. Prevalence of nonadherence with maintenance mesalarnine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2933.
32. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009; 137: 1934-1943.